Encompass Health (EHC)
(Delayed Data from NYSE)
$94.50 USD
-0.23 (-0.24%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $94.48 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$94.50 USD
-0.23 (-0.24%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $94.48 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
Why Should You Add Universal Health (UHS) to Your Portfolio?
by Zacks Equity Research
Backed by its strategic measures, solid segmental contributions and a strong solvency level, Universal Health (UHS) holds potential to reap benefits for investors.
Cooper Companies (COO) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter earnings reflect solid segmental performance.
Encompass Health (EHC) Opens Hospital, Boosts Florida Footprint
by Zacks Equity Research
Encompass Health (EHC) opens an inpatient rehabilitation hospital in Pensacola, FL aimed at providing improved health outcomes across the state.
Patterson Companies (PDCO) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter 2022 results benefit from strong segmental performance.
Veeva Systems (VEEV) Q2 Earnings Beat Estimates, '22 View Up
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q2 results reflect impressive performances by both its segments.
Catalent's (CTLT) Q4 Earnings Top Estimates, Margins Rise
by Zacks Equity Research
Catalent's (CTLT) robust performance across the majority of its segments drives its fourth-quarter fiscal 2021 top line.
Encompass Health's (EHC) Growth View Makes It a Good Buy
by Sapna Bagaria
Ageing population, building of hospitals and other operational efforts poise Encompass Health (EHC) well for long-term growth, thus making it a good investment option.
EHC vs. AMED: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EHC vs. AMED: Which Stock Is the Better Value Option?
New Strong Buy Stocks for August 27th
by Zacks Equity Research
CTRN, EHC, HMC, PPC, and MNTX have been added to the Zacks Rank #1 (Strong Buy) List on August 27, 2021.
Cooper Companies (COO) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter results are likely to reflect segmental strength.
Phibro (PAHC) Q4 Earnings Match Estimates, Margins Down
by Zacks Equity Research
Phibro (PAHC) sees revenue growth in fourth-quarter fiscal 2021 due to strength in all three segments.
Encompass Health (EHC) Down 4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What's in Store for Patterson Companies' (PDCO) Q1 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect improvement at Dental segment.
Medtronic's (MDT) Q1 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Medtronic's (MDT) fiscal first-quarter results reflect a strong recovery from the impact of the COVID-19 pandemic on elective procedures that the company experienced in 2020.
Zacks.com featured highlights include: Encompass Health Corp, Perficient and Saia
by Zacks Equity Research
Zacks.com featured highlights include: Encompass Health Corp, Perficient and Saia
3 Stocks With Upgraded Broker Ratings to Buy Right Away
by Swayta Shah
By following broker ratings upgrades, you can easily find profitable stocks. So, we choose Encompass Health (EHC), Perficient (PRFT) and Saia (SAIA) as these have witnessed ratings upgrade.
Alcon (ALC) Q2 Earnings Top Estimates, 2021 Guidance Up
by Zacks Equity Research
Alcon (ALC) records the highest sales in the second quarter of 2021 since its spin-off.
Here's Why You Should Invest in Encompass Health (EHC) Now
by Zacks Equity Research
Encompass Health (EHC) is riding on top-line growth, higher patient volumes, continuous facility expansions and reducing debt levels.
National Vision (EYE) Q2 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Strength in Americas Best and Eyeglass World brands drove National Vision's (EYE) revenues in the second quarter of 2021.
New Strong Buy Stocks for August 12th
by Zacks Equity Research
EHC, HVT, VRTV, HAFC, and STRL have been added to the Zacks Rank #1 (Strong Buy) List on August 12, 2021.
Accuray (ARAY) Posts In-Line Q4 Earnings, Beats on Revenues
by Zacks Equity Research
Accuray (ARAY) registers growth in Service and Product revenues during fiscal Q4.
Haemonetics (HAE) Q1 Earnings Top Estimates, Margins Improve
by Zacks Equity Research
Ongoing recovery in businesses, especially Hospital, and the initial Plasma Persona rollouts drove Haemonetics (HAE) fiscal first-quarter revenues.
EHC vs. AMED: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EHC vs. AMED: Which Stock Is the Better Value Option?
Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
A faster-than-expected recovery in base business and stabilized demand for COVID-19 testing instill optimism in Quest Diagnostics (DGX).
Inari Medical (NARI) Q2 Earnings Lag, Revenues Top Estimates
by Zacks Equity Research
Inari Medical's (NARI) second-quarter 2021 results benefit from significant revenue growth and gross margin expansion.